NeoPhore Limited, a cancer immuno-oncology company, have announced the appointment of Jeffrey Roix as Chief Executive Officer, with immediate effect.
Jeffrey brings with him over 10 years’ experience in drug discovery, having worked in academic, pharma and startup settings. He was previously Chief Operating Officer, at Cambridge-based PhoreMost Ltd, where he was responsible for launching company operations and building the company’s initial scientific and portfolio strategy. He was instrumental in setting up NeoPhore.
Jeffrey has held various positions at institutions including Novartis Institute for Biomedical Research, Constellation Pharmaceuticals and Massachusetts Institute of Technology, in Cambridge MA where he specialized in cancer biology and metabolism. Jeffrey obtained his Bachleor’s degree in biology at the Harvard Extension School.
NeoPhore is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. NeoPhore’s drugs are designed to promote sensitivity and create lasting efficacy in non-immunogenic and immunogenic cancer types, particularly in combination with immune checkpoint drugs. Their mechanism and activity is differentiated from many competing strategies for combination immune-oncology therapy: NeoPhore’s drugs are first-in-class inhibitors of mismatch DNA-repair, which clinical, genetic and laboratory evidence suggests is a fundamental approach to enhance cancer immunity.
Commenting on the appointment, NeoPhore Chairman, Robert James, said: “Jeff’s experience in preclinical discovery and clinical translation, will be invaluable as we build on the discoveries that underpin the formation of NeoPhore to develop novel small-molecule drugs to stimulate immunity in diverse cancers.”
Jeff Roix, CEO of NeoPhore, commented: “I am very excited to be working with our team in an innovative venture to create a next generation of cancer immunotherapy medicines.”